ID

6416

Description

Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma DISEASE CHARACTERISTICS: - Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL) by an excisional biopsy of a lymph node or an extensive biopsy of an extranodal involvement (if there is no lymph node involvement) - CD20^+ B-cell lymphoma or CD20^- B-cell and T-cell lymphoma allowed - B-cell NHL including the following: Stage III follicular lymphoma; Stage III follicular lymphoma and diffuse B-cell lymphoma; Lymphoblastic precursor B-cell lymphoma; Diffuse large cell B-cell lymphoma; Centroblastic; Immunoblastic; Plasmablastic; Anaplastic large cell; T-cell-rich B-cell lymphoma; Primary effusion lymphoma; Intravasal B-cell lymphoma; Primary mediastinal B-cell lymphoma; Mantle zone lymphoma, blastoid; Burkitt's lymphoma; Burkitt-like lymphoma; Aggressive marginal zone lymphoma (monocytoid); - T-cell NHL including the following: Lymphoblastic precursor T-cell lymphoma; Peripheral T-cell lymphoma (PTCL) not otherwise specified (NOS); Lennert's lymphoma; T-zone lymphoma; T-cell lymphoma of the angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) type; Anaplastic large cell lymphoma; ALK^+ - ALK^-; Extranodal NK/T-cell lymphoma, nasal type; Intestinal T/NK-cell lymphoma (with or without enteropathy); Hepatosplenic gamma-delta lymphoma; Subcutaneous panniculitis-like PTCL; Aggressive T/NK PTCL; Anaplastic large-cell NHL, NOS - Bone marrow involvement no more than 25% - No lymphoma that is clearly restricted to the CNS or originating from the gastrointestinal tract PATIENT CHARACTERISTICS: Age - 61 to 80 Performance status - ECOG 0-2 OR - Karnofsky 60-100% Life expectancy - Not specified Hematopoietic - WBC at least 2,500/mm^3; Platelet count at least 100,000/mm^3 Hepatic - Bilirubin no greater than 2 times upper limit of normal (ULN); No active hepatitis infection Renal - Creatinine no greater than 2 times ULN Cardiovascular - No Canadian Cardiovascular Society class III or IV angina pectoris - No New York Heart Association class III or IV cardiac failure - Ejection fraction at least 50% - Fractional shortenings at least 25% by echocardiography or nuclear medicine examination Pulmonary - FEV1 at least 50% - Diffusion capacity at least 50% Other - No uncontrolled diabetes mellitus - No known hypersensitivity to any study medications - No other concurrent malignancy - HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - No prior chemotherapy Endocrine therapy - Not specified Radiotherapy - No prior radiotherapy Surgery - Not specified Other - Must not have already initiated lymphoma therapy (except for the prephase treatment specified for this study) - No other concurrent lymphoma therapy - No concurrent participation in another treatment study

Mots-clés

  1. 09/12/2013 09/12/2013 - Martin Dugas
  2. 22/12/2014 22/12/2014 - Martin Dugas
Téléchargé le

22 décembre 2014

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0 Legacy

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility NCT00052936 NHL

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Disease characteristics
Description

Disease characteristics

Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL) by an excisional biopsy of a lymph node or an extensive biopsy of an extranodal involvement (if there is no lymph node involvement); CD20+ B-cell lymphoma or CD20- B-cell and T-cell lymphoma allowed
Description

Aggressive non-Hodgkin's lymphoma (NHL)

Type de données

boolean

Alias
UMLS CUI-1
C1332225
B-cell NHL including the following: Stage III follicular lymphoma; Stage III follicular lymphoma and diffuse B-cell lymphoma; Lymphoblastic precursor B-cell lymphoma; Diffuse large cell B-cell lymphoma; Centroblastic; Immunoblastic; Plasmablastic; Anaplastic large cell; T-cell-rich B-cell lymphoma; Primary effusion lymphoma; Intravasal B-cell lymphoma; Primary mediastinal B-cell lymphoma; Mantle zone lymphoma, blastoid; Burkitt's lymphoma; Burkitt-like lymphoma; Aggressive marginal zone lymphoma (monocytoid)
Description

B-cell NHL

Type de données

boolean

Alias
UMLS CUI-1
C0079731
T-cell NHL including the following: Lymphoblastic precursor T-cell lymphoma; Peripheral T-cell lymphoma (PTCL) not otherwise specified (NOS); Lennert's lymphoma; T-zone lymphoma; T-cell lymphoma of the angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) type; Anaplastic large cell lymphoma; ALK^+ - ALK^-; Extranodal NK/T-cell lymphoma, nasal type; Intestinal T/NK-cell lymphoma (with or without enteropathy); Hepatosplenic gamma-delta lymphoma; Subcutaneous panniculitis-like PTCL; Aggressive T/NK PTCL; Anaplastic large-cell NHL, NOS
Description

T-cell NHL

Type de données

boolean

Alias
UMLS CUI-1
C0079772
Bone marrow involvement no more than 25%
Description

Bone marrow involvement

Type de données

boolean

Alias
UMLS CUI-1
C1517677
No lymphoma that is clearly restricted to the CNS or originating from the gastrointestinal tract
Description

CNS or GI lymphoma

Type de données

boolean

Patient characteristics and prior concurrent therapy
Description

Patient characteristics and prior concurrent therapy

Age 61 to 80
Description

Age

Type de données

boolean

Alias
UMLS CUI-1
C0001779
ECOG 0-2 OR - Karnofsky 60-100%
Description

Performance Status

Type de données

boolean

Alias
UMLS CUI-1
C1520224
WBC at least 2,500/mm^3
Description

WBC at least 2,500/mm^3

Type de données

float

Unités de mesure
  • mm^3
Alias
UMLS CUI-1
C0023508
mm^3
Platelet count at least 100,000/mm^3
Description

Platelet count at least 100,000/mm^3

Type de données

float

Unités de mesure
  • mm^3
Alias
UMLS CUI-1
C1287267
mm^3
Bilirubin no greater than 2 times upper limit of normal (ULN)
Description

Bilirubin no greater than 2 times upper limit of normal (ULN)

Type de données

boolean

Alias
UMLS CUI-1
C0201913
No active hepatitis infection
Description

No active hepatitis infection

Type de données

boolean

Alias
UMLS CUI-1
C0332197
UMLS CUI-2
C0744827
Creatinine no greater than 2 times ULN
Description

Creatinine

Type de données

boolean

Alias
UMLS CUI-1
C0010294
No Canadian Cardiovascular Society class III or IV angina pectoris; No New York Heart Association class III or IV cardiac failure; Ejection fraction at least 50%; Fractional shortenings at least 25% by echocardiography or nuclear medicine examination
Description

Absence of heart failure

Type de données

boolean

Alias
UMLS CUI-1
C0332197
UMLS CUI-2
C0018801
FEV1 at least 50%
Description

FEV1

Type de données

boolean

Alias
UMLS CUI-1
C0849974
Diffusion capacity at least 50%
Description

Diffusion capacity

Type de données

boolean

Alias
UMLS CUI-1
C0231971
No uncontrolled diabetes mellitus; No known hypersensitivity to any study medications; No other concurrent malignancy; HIV negative
Description

Other

Type de données

boolean

No prior chemotherapy; No prior radiotherapy; Must not have already initiated lymphoma therapy (except for the prephase treatment specified for this study); No other concurrent lymphoma therapy; No concurrent participation in another treatment study
Description

Prior concurrent therapy

Type de données

boolean

Similar models

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Disease characteristics
Aggressive Non-Hodgkin Lymphoma
Item
Histologically confirmed aggressive non-Hodgkin's lymphoma (NHL) by an excisional biopsy of a lymph node or an extensive biopsy of an extranodal involvement (if there is no lymph node involvement); CD20+ B-cell lymphoma or CD20- B-cell and T-cell lymphoma allowed
boolean
C1332225 (UMLS CUI-1)
B-cell NHL
Item
B-cell NHL including the following: Stage III follicular lymphoma; Stage III follicular lymphoma and diffuse B-cell lymphoma; Lymphoblastic precursor B-cell lymphoma; Diffuse large cell B-cell lymphoma; Centroblastic; Immunoblastic; Plasmablastic; Anaplastic large cell; T-cell-rich B-cell lymphoma; Primary effusion lymphoma; Intravasal B-cell lymphoma; Primary mediastinal B-cell lymphoma; Mantle zone lymphoma, blastoid; Burkitt's lymphoma; Burkitt-like lymphoma; Aggressive marginal zone lymphoma (monocytoid)
boolean
C0079731 (UMLS CUI-1)
T-cell NHL
Item
T-cell NHL including the following: Lymphoblastic precursor T-cell lymphoma; Peripheral T-cell lymphoma (PTCL) not otherwise specified (NOS); Lennert's lymphoma; T-zone lymphoma; T-cell lymphoma of the angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) type; Anaplastic large cell lymphoma; ALK^+ - ALK^-; Extranodal NK/T-cell lymphoma, nasal type; Intestinal T/NK-cell lymphoma (with or without enteropathy); Hepatosplenic gamma-delta lymphoma; Subcutaneous panniculitis-like PTCL; Aggressive T/NK PTCL; Anaplastic large-cell NHL, NOS
boolean
C0079772 (UMLS CUI-1)
Bone marrow involvement
Item
Bone marrow involvement no more than 25%
boolean
C1517677 (UMLS CUI-1)
CNS or GI lymphoma
Item
No lymphoma that is clearly restricted to the CNS or originating from the gastrointestinal tract
boolean
Item Group
Patient characteristics and prior concurrent therapy
Age
Item
Age 61 to 80
boolean
C0001779 (UMLS CUI-1)
Performance Status
Item
ECOG 0-2 OR - Karnofsky 60-100%
boolean
C1520224 (UMLS CUI-1)
WBC
Item
WBC at least 2,500/mm^3
float
C0023508 (UMLS CUI-1)
Platelets
Item
Platelet count at least 100,000/mm^3
float
C1287267 (UMLS CUI-1)
Bilirubin
Item
Bilirubin no greater than 2 times upper limit of normal (ULN)
boolean
C0201913 (UMLS CUI-1)
Absence of active Hepatitis
Item
No active hepatitis infection
boolean
C0332197 (UMLS CUI-1)
C0744827 (UMLS CUI-2)
Creatinine
Item
Creatinine no greater than 2 times ULN
boolean
C0010294 (UMLS CUI-1)
Absence of heart failure
Item
No Canadian Cardiovascular Society class III or IV angina pectoris; No New York Heart Association class III or IV cardiac failure; Ejection fraction at least 50%; Fractional shortenings at least 25% by echocardiography or nuclear medicine examination
boolean
C0332197 (UMLS CUI-1)
C0018801 (UMLS CUI-2)
FEV1
Item
FEV1 at least 50%
boolean
C0849974 (UMLS CUI-1)
Diffusion capacity
Item
Diffusion capacity at least 50%
boolean
C0231971 (UMLS CUI-1)
Other
Item
No uncontrolled diabetes mellitus; No known hypersensitivity to any study medications; No other concurrent malignancy; HIV negative
boolean
Prior concurrent therapy
Item
No prior chemotherapy; No prior radiotherapy; Must not have already initiated lymphoma therapy (except for the prephase treatment specified for this study); No other concurrent lymphoma therapy; No concurrent participation in another treatment study
boolean

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial